Effect of edaravin combined with cerebroside-kinin maintenance of neurological function in patients with severe craniocerebral injury
10.3760/cma.j.issn.1671-0282.2019.03.009
- VernacularTitle:依达拉奉辅助脑苷肌肽对重症颅脑损伤患者的保护作用
- Author:
Lichao FANG
1
;
Kun AN
;
Yanqin HUA
;
Cheng FAN
;
Xiaomin WANG
;
Shigang QIAO
Author Information
1. 苏州市相城人民医院重症医学科 215131
- Keywords:
Severe craniocerebral injury;
Edaravone;
Glial fiber acidic protein;
Ubiquitin carboxyl terminal-L1
- From:
Chinese Journal of Emergency Medicine
2019;28(3):319-323
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the influence of edaravin combined with cerebroside-kinin on the level of glial fiber acidic protein (GFAP) and ubiquitin carboxyl terminal-L1 (UCH-L1) in the treatment of severe craniocerebral injury.Methods From January 2016 to December 2017,a total of 123 patients with severe craniocerebral injury were selected in our hospital,and randomly(random number) assigned to the observation group (61 cases) and control group (62 cases).Patients in the control group were given cerebroside-kinin,and patients in the observation group were given cerebroside-kinin and edaravone.The acute physiology and chronic health evaluation score (APACHE Ⅱ),activities of daily living (ADL) score,serum malonaldehyde (MDA),superoxide dismutase (SOD),myeloperoxidase (MPO),matrix metalloprotein 9 (MMP-9),GFAP and UCH-L1 before and after treatment were observed.The side effects were also recorded.Results The APACHE Ⅱ score was significantly reduced in both groups after treatment (P=0.008;P=0.003),and was lower in the observation group than that in the control group (P=0.013).The ADL score of both groups increased after treatment (P=0.025;P=0.008),and was higher in the observation group than that in the control group (P=0.012).After treatment the levels of MDA,SOD and MPO in the observation group were significantly higher than those in the control group (P＜0.05);the level of MMP-9 in the observation group was significantly lower than that in the control group (P=0.012);the levels of GFAP and UCH-L 1 in the observation group were significantly higher than those in the control group (P=0.014;P=0.035).There was no significant difference of the total side effect incidence between the observation group and the control group (8.06％ vs 9.83％,x 2=0.088,P=0.719).Conclusions The treatment by edaravone combined with cerebroside-kinin on severe craniocerebral injury may effectively protect the nerve cells,improve nerve function,clinical efficacy and the body's antioxidant capacity,reduce the serum levels of GFAP,UCH-L1,and have better safety.
